Crossmark

Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression

Crossref DOI link: https://doi.org/10.1038/s41563-020-00849-5

Published Online: 2020-11-30

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maller, Ori https://orcid.org/0000-0002-4149-0179
Drain, Allison P.

Barrett, Alexander S.

Borgquist, Signe

Ruffell, Brian https://orcid.org/0000-0002-3846-6872
Zakharevich, Igor

Pham, Thanh T.

Gruosso, Tina

Kuasne, Hellen

Lakins, Johnathon N.

Acerbi, Irene

Barnes, J. Matthew

Nemkov, Travis https://orcid.org/0000-0001-8566-7119
Chauhan, Aastha

Gruenberg, Jessica

Nasir, Aqsa https://orcid.org/0000-0003-3134-2874
Bjarnadottir, Olof

Werb, Zena

Kabos, Peter

Chen, Yunn-Yi

Hwang, E. Shelley

Park, Morag https://orcid.org/0000-0001-5400-606X
Coussens, Lisa M. https://orcid.org/0000-0003-2389-1865
Nelson, Andrew C. https://orcid.org/0000-0002-4741-0010
Hansen, Kirk C.

Weaver, Valerie M. https://orcid.org/0000-0003-4786-6752
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | National Institutes of Health (T32 CA 108462)

U.S. Department of Health & Human Services | National Institutes of Health (TL1 TR001081)

U.S. Department of Health & Human Services | National Institutes of Health (T32 HL007171)

U.S. Department of Health & Human Services | National Institutes of Health (R01 CA057621)

U.S. Department of Health & Human Services | National Institutes of Health (T32 CA 108462)

U.S. Department of Health & Human Services | National Institutes of Health (R01 CA057621)

Vetenskapsrådet

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA222508-01)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R33 CA183685)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA192914)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA174929)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA222508-01)

Masonic Cancer Center at the University of Minnesota
License Information

Text and Data Mining valid from 2020-11-30

Version of Record valid from 2020-11-30
More Information

Article History

Received: 8 December 2017

Accepted: 30 September 2020

First Online: 30 November 2020

Competing interests

: The authors declare the following competing interests: L.M.C. is a paid consultant for Cell Signaling Technologies, Shasqi Inc., and AbbVie Inc., and received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma and NanoString Technologies, and is a member of the scientific advisory boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc., Verseau Therapeutics, Cytomix Therapeutics, Inc. and Kineta Inc. T.N. and K.C.H. are co-founders of Omix Technologies.

Document is current

Any future updates will be listed below